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Abstract
Introduction: In the present study, we sought to identify markers in patients with anti-neutrophil cytoplasmic antibody
(ANCA)-associated vasculitis (AAV) that distinguish those achieving remission at 6 months following rituximab or
cyclophosphamide treatment from those for whom treatment failed in the Rituximab in ANCA-Associated Vasculitis (RAVE) trial.
Methods: Clinical and flow cytometry data from the RAVE trial were downloaded from the Immunology Database and
Analysis Portal and Immune Tolerance Network TrialShare public repositories. Flow cytometry data were analyzed using
validated automated gating and joined with clinical data. Lymphocyte and granulocyte populations were measured in patients
who achieved or failed to achieve remission.
Results: There was no difference in lymphocyte subsets and treatment outcome with either treatment. We defined a
Granularity Index (GI) that measures the difference between the percentage of hypergranular and hypogranular
granulocytes. We found that rituximab-treated patients who achieved remission had a significantly higher GI at baseline
than those who did not (p = 0.0085) and that this pattern was reversed in cyclophosphamide-treated patients (p = 0.037).
We defined optimal cutoff values of the GI using the Youden index. Cyclophosphamide was superior to rituximab in
inducing remission in patients with GI below −9.25 % (67 % vs. 30 %, respectively; p = 0.033), whereas rituximab was
superior to cyclophosphamide for patients with GI greater than 47.6 % (83 % vs. 33 %, respectively; p = 0.0002).
Conclusions: We identified distinct subsets of granulocytes found at baseline in patients with AAV that predicted
whether they were more likely to achieve remission with cyclophosphamide or rituximab. Profiling patients on the basis
of the GI may lead to more successful trials and therapeutic courses in AAV.
Trial registration: ClinicalTrials.gov identifier (for original study from which data were obtained): NCT00104299. Date of
registration: 24 February 2005.
Introduction
Granulomatosis with polyangiitis (GPA) and microscopic
polyangiitis (MPA) are severe, necrotizing small-vessel vas-
culitides. These diseases are classified as anti-neutrophil
cytoplasmic antibody–associated vasculitis (AAV) on
the basis of their association with anti-neutrophil
cytoplasmic antibodies (ANCA) that target proteinase 3
(PR3) or myeloperoxidase (MPO) antigens [1]. Until re-
cently, cyclophosphamide and glucocorticoids were the
mainstays for the induction of remission. However, the
Rituximab in ANCA-Associated Vasculitis (RAVE) trial
(ClinicalTrials.gov identifier: NCT00104299) clearly de-
monstrated the non-inferiority of rituximab to cyclo-
phosphamide for the induction of remission [2].
RAVE was a prospective, randomized, active-controlled,
double-blinded, double-dummy, phase II/III, multicenter
interventional study involving 197 participants in which
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rituximab was compared with cyclophosphamide for the
induction of remission in AAV. Its primary endpoint was
the induction of complete remission, defined as a disease
score of zero and a complete tapering off from steroids.
RAVE’s primary results demonstrated that rituximab was
non-inferior to cyclophosphamide for the induction of
complete remission and was more efficacious than cyclo-
phosphamide for the induction of remission in patients
with relapsing disease [2].
Nonetheless, approximately 35 % of patients treated
with rituximab and 47 % of patients treated with cyclo-
phosphamide failed to achieve complete remission, with
no clinical or biochemical markers identified so far that
correlate with treatment outcome [2, 3]. We aimed to
address this lacuna by applying computational ap-
proaches to reanalyze publicly available data from the
first 6 months of the RAVE trial. These data were ob-
tained from two publicly accessible sources: Immun-
ology Database and Analysis Portal (ImmPort;
import.niaid.nih.gov or immport.org; accession number
SDY91) [4] and the Immune Tolerance Network’s (ITN)
TrialShare ([5]; accession number ITN021AI).
We hypothesized that patients who achieved complete
remission on either rituximab or cyclophosphamide had
differences in their white blood cell compartment detect-
able at the beginning of their treatment course, com-
pared with those who failed remission. To test our
hypothesis, we reanalyzed 1150 flow cytometry sample
measurements using the automated-gating software tool
Flow cytometry Clustering without K (ImmPort-FLOCK)
[6], available online at the ImmPort website (immport.-
niaid.nih.gov). We developed and validated a relational
database implementation of the FLOCK-generated
automated-gating results for rapid integration with the
trial’s other mechanistic and clinical data. Using this ap-
proach, we were able to compare the percentages of total
lymphocytes, lymphocyte subsets, and granulocyte sub-
sets in patients with AAV who met the primary endpoint
outcome of the RAVE trial with those who did not.
Methods
Study design and data sources
Subjects in this study were enrolled in the RAVE trial
(ClinicalTrials.gov identifier: NCT00104299) [2]. Dei-
dentified clinical and partial mechanistic data from the
first 6 months of the RAVE trial are publicly available
and were used in the present study. As part of the trial,
investigators ran flow cytometry assays on whole-blood
specimens from 197 study participants. We downloaded
these data, as well as clinical trial data, from the ITN
TrialShare [5] from the first 6 months of the trial (the
only time period for which the data were available). This
yielded a total of 1150 FCS-formatted files and 22 clin-
ical data files. Both clinical trial data and flow cytometry
data are now also available from the National Institute
of Allergy and Infectious Diseases (NIAID) ImmPort
database [7]. Regarding the reanalysis of such open clin-
ical trials data, we did not have to contact the original
trialists for this study; questions regarding the RAVE
study design were addressed by review of the primary
publications from the RAVE trial. Technical questions
regarding the clinical or mechanistic data files were
directed to the study coordinator at the ITN TrialShare
Network.
Description of the flow cytometry files
The RAVE trial serially collected whole blood that was
assayed by flow cytometry using standardized protocols.
For each patient, blood was collected at an initial screen-
ing visit, as well as at week 2 and months 1, 2, 4, 6, 9,
12, 15 and 18 following enrollment [8]. Per protocol, a
total of 15 antibody-staining panels were assessed by
flow cytometry on each sample. Only one panel, asses-
sing the B1 B-cell population through surface protein
expression of cluster of differentiation 1c (CD1c), CD5,
CD19, CD21 or CD23, was publicly available at the time
of our study and was downloaded.
ImmPort-FLOCK analysis of flow cytometry data files
FCS files were uploaded and analyzed using the ImmPort
web-based FLOCK service (ImmPort-FLOCK) [9]. We
chose ImmPort-FLOCK over other auto-gating algorithms
because it is relatively robust to intersample fluorescence
variability [6] and because the algorithm performed well
in comparison with other auto-gating algorithms [10].
Version 1 of ImmPort-FLOCK, previously validated in the
analysis of small-volume flow cytometry data [6, 11, 12],
was used for our analyses with default settings. The ana-
lysis results were visualized using the ImmPort-FLOCK
data visualization tool (Additional file 1, panel a).
We then downloaded the results for each analyzed
FCS file and processed them for upload into a relational
database (MySQL; Oracle, Redwood City, CA, USA).
The database also contained the clinical data, enabling
joining with the ImmPort-FLOCK results. SQL queries
were used to extract flow cytometry results as described
below.
Using ImmPort-FLOCK database to identify cell
populations
A description of the automated gating in the ImmPort-
FLOCK algorithm was previously published [6]. Each
cell population identified by ImmPort-FLOCK is defined
by parameters measured by the flow cytometer: forward
scatter (FSC), side scatter (SSC), and fluorescence signal
intensity. An example of ImmPort-FLOCK output is
shown in Additional file 1, panel a. Each cell population
(cluster) identified by ImmPort-FLOCK is color-coded
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and represented by a vector of signal values on a scale of
1–4, along with the corresponding percentage of cells in
a cluster relative to the total cell population. The signal
values represent a scale that qualitatively describes
expression levels: 1 = negative, 2 = low, 3 = positive, and
4 = high. For example, a population of cells with the
values FSC = 2, SSC = 1, CD19 = 3, CD21 = 2, CD23 = 2,
CD5 = 2 and CD1c = 1 would be small (FSC = 2); agranu-
lar (SSC = 1); positive for CD19; weakly positive for
CD21, CD23 and CD5; and negative for CD1c. These
values are normalized within each file, allowing compari-
son across different samples. Additional file 1, panel b, is
a summary of expression profiles for each population in
a typical flow cytometry file, with a total of 21 popula-
tions identified by ImmPort-FLOCK. Auto-gating results
from all 1150 FCS files were stored in a relational data-
base and linked to each subject’s clinical data. The data-
base was then queried to identify cell counts within
specific populations. Additional file 1, panel c, shows an
FSC-SSC dot plot to show how each population was de-
fined on the basis of size and granularity. Table 1 shows
the queries we used to identify the different populations.
To validate our method, 100 FCS files were randomly
chosen from the total set and analyzed manually by two
independent immunologists using the software package
FlowJo (Tree Star, Ashland, OR, USA) and compared
with ImmPort-FLOCK results.
Granularity Index
The size and granularity of cells are measured indirectly
by FSC and SSC signals, respectively. Within the gran-
ulocyte population, we defined two populations of
granulocytes on the basis of granularity: cells with high
granularity (Fig. 3a), which we call hypergranular granu-
locytes, and cells with lower granularity, which we term
hypogranular granulocytes. We calculate a GI by taking
the absolute difference between the percentages of
these two populations, potentially ranging from −100 %
to +100 %. For example, if hypergranular granulocytes
constitute 40 % of the total white blood cell population
and hypogranular granulocytes constitute 20 % the total
white blood cell population, then the Granularity Index
(GI) is 20 %. The specific cell population query defini-
tions we used for these two populations are shown in
Table 1.
Statistical analysis
Statistical analyses were performed using the R statistical
software package. Two-sample comparisons were per-
formed with the use of an unpaired Kruskal-Wallis rank-
sum non-parametric test for continuous measures and a
two-tailed Fisher’s exact test for binary measures. R2 cor-
relation values were calculated using a linear regression
model with Pearson correlation coefficients. Null hypo-
theses were rejected at the 0.05 significance level.
Results
Analytical process
Figure 1 shows an overview of our analytical process.
Publicly available, raw, deidentified, individual-level data
from the RAVE trial were obtained from ITN TrialShare
and ImmPort. These data covered 197 individuals stud-
ied over 6 months. Whole blood had been obtained from
these individuals during the RAVE study, and cell popu-
lations were analyzed by flow cytometry using stan-
dardized protocols. A total of 1150 flow cytometry files
were reanalyzed using the automated gating tool
ImmPort-FLOCK, and the results were stored in a data-
base. We used this database to execute structured queries
to retrieve flow cytometry associated with clinical data.
Validation of the ImmPort-FLOCK identified cell
populations and database
We first validated our approach for extracting cell popu-
lations by comparing ImmPort-FLOCK auto-gating re-
sults with the current gold standard of manual gating of
flow cytometry data. The results of this validation are
shown in Fig. 2. We found that cell percentages identi-
fied through automated gating correlated well with re-
sults from manual gating obtained from two
immunologists identifying lymphocytes and granulocytes
(r2 = 0.959 and 0.873, respectively). Correlation was
lower for automated identification of monocytes: r2 =
0.334. The inter-rater correlation between the two im-
munologists was also very good for lymphocytes, mono-
cytes and granulocytes (r2 = 0.986, r2 = 0.956 and r2 =
0.717, respectively). We also validated our approach
against published cell counts from the RAVE trial that
showed a drop in the absolute CD19+ lymphocyte counts.
Table 1 Queries used to identify different cell populations using
our database storing results from ImmPort-FLOCK
Cell populations Queries used
Total lymphocytes FSC ≤ 2 AND SSC = 1
CD1c + lymphocytes FSC ≤ 2 AND SSC = 1 AND CD1c≥ 2
CD5+ lymphocytes FSC ≤ 2 AND SSC = 1 AND CD5≥ 2
CD19+ lymphocytes FSC ≤ 2 AND SSC = 1 AND CD19≥ 2
CD21+ lymphocytes FSC ≤ 2 AND SSC = 1 AND CD21≥ 2
CD23+ lymphocytes FSC ≤ 2 AND SSC = 1 AND CD23≥ 2
Total monocytes FSC ≥ 3 AND SSC ≤ 2
Total granulocytes ((FSC≥ 3 AND SSC ≥ 3) OR (FSC≤ 2 AND
SSC ≥ 2))
Hypergranular granulocytes FSC ≥ 1 AND SSC = 4
Hypogranular granulocytes (FSC ≤ 2 AND SSC = 3) OR (FSC≤ 2 AND
SSC = 2) OR (FSC ≥ 3 AND SSC = 3)
CD cluster of differentiation, FSC forward scatter, ImmPort-FLOCK, Immunology
Database and Analysis Portal flow cytometry clustering without K, SSC side scatter
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ImmPort-FLOCK results were highly congruent with the
published RAVE results obtained by manual analysis
(Fig. 2c and d) with an r2 of 0.99 (Additional file 2).
Patient characteristics at screening
Of the 197 study participants enrolled in the RAVE trial,
187 patients had flow cytometry measurements obtained
from samples at their screening visit, before treatment.
These 187 patients included 94 male and 93 female pa-
tients with a mean age of 52.9 years. All patients had severe
disease at baseline (mean Birmingham Vasculitis Activity
Score for Wegener’s granulomatosis 8, range 3–23). Diag-
noses comprised 137 with GPA, 48 with MPA, and 1 with
indeterminate disease, and 1 had a missing diagnosis. Of
the 187 patients, 123 were positive for anti-PR3, 64 were
positive for anti-MPO antibodies, 93 were randomized to
cyclophosphamide treatment and 94 were randomized to
receive rituximab.
The primary endpoint of the RAVE trial was the in-
duction of complete remission, defined as a disease score
of zero and a complete tapering off from steroids. After
6 months in the trial, 48 (52 %) of 93 in the cyclophos-
phamide group reached the primary endpoint, compared
with 60 (64 %) of 94 in the rituximab group. In congru-
ence with previously published data from the RAVE trial,
we did not identify clinical variables able to discriminate
Fig. 1 Overview of the analytical process, starting with open access clinical trial data. Solid black arrows represent work carried out by the primary
investigators. White arrows represent work done in the present study, enabled by the public accessibility of the original raw trial data. Dashed
black arrows represent future work that could be triggered by the reanalysis process
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Fig. 2 Validation of the Immunology Database and Analysis Portal flow cytometry clustering without K (ImmPort-FLOCK). Cell subset percentages by
automated identification were validated against manual gating for the identification of immune cell populations on the basis of size and granularity
(forward scatter and side scatter, respectively). One hundred random flow cytometry files were independently analyzed by two immunologists using
standard FlowJo software. a Scatterplots between the two immunologists show significant concordance in the identification of different cell
populations. b Similar correlation was seen for granulocyte and lymphocyte percentages between automated analysis and the average of the two
immunologists (shaded area represents the 95 % confidence interval of the regression line; p values based on Pearson correlation test). c Originally
published figure showing the drop in CD19+ B-cell counts with rituximab or control (cyclophosphamide) treatment generated using manual
gating of flow cytometry results (Reproduced with permission from [2]. d Results obtained through automated identification of the CD19+
lymphocyte population. Results shown in (c) and (d) represent median cell counts. ANCA anti-neutrophil cytoplasmic antibodies, CD cluster of
differentiation, MPO myeloperoxidase, PR3 proteinase 3
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between those who met the primary endpoint outcome
and those who did not (Table 2).
Overview of population changes with treatment outcome
We hypothesized that patients who achieved complete
remission by month 6 in either arm of the trial had dif-
ferential changes at baseline (i.e., before the initiation of
treatment) in their leukocyte composition compared
with those who did not. We examined the percentage of
major lymphocyte subpopulations as well as the percent-
age of granulocytes. There was no difference in the per-
centage of major lymphocyte subsets at baseline (CD1c+,
CD5+, CD19+, CD21+ or CD23+ lymphocytes) between
patients who achieved or failed to achieve complete re-
mission on either rituximab or cyclophosphamide (data
not shown).
Distinct granulocyte populations at baseline are
associated with treatment outcome
SSC signals can be used as a rough semiquantitative
measure of granulocyte granularity and primary granule
secretory responses, thus providing information on cell
activation status [13]. Using ImmPort-FLOCK, we iden-
tified distinct granulocyte subsets on the basis of size
and granularity and calculated a GI as described in the
Methods section. We assigned this index to each indi-
vidual at baseline. We found that on day 0, the GI was
higher in the 60 rituximab-treated patients who achieved
complete remission than in the 34 patients who did not
(p = 0.0085) (Fig. 3b). In juxtaposition, the GI was lower
in the 48 cyclophosphamide-treated patients who
achieved complete remission than in the 45 patients
who did not (p = 0.037) (Fig. 3c).
We found no association between the GI at baseline and
baseline ANCA titers (r2 = 0.0016), disease severity score
(r2 = 0.001), age (r2 = 0.0056), sex (p = 0.46) or relapsing
disease at baseline (p = 0.10). However, individuals with
anti-PR3 ANCA vasculitis had significantly higher GI
compared with those with anti-MPO disease (p = 0.017).
As shown in Table 2, there was no difference in the attain-
ment of primary endpoint outcome and the serological
subtype (anti-PR3 vs. anti-MPO disease).
Next, we calculated the optimal cutoff of GI values
using the Youden index [14] to discriminate between
those who achieved or failed to achieve the primary end-
point outcome. The optimal cutoff for identifying patients
failing rituximab treatment was calculated as −9.25 %.
Fourteen (41.2 %) of the thirty-four patients who failed to
achieve remission on rituximab had a GI below this cutoff
value, compared with only six (10 %) of sixty patients who
achieved remission (p = 0.0011, likelihood ratio [LR] 4.12,
95% confidence interval [CI] 1.74–9.72). Of note, lower GI
values correlated with higher likelihood of failure to
rituximab. For example, only 2 (3.3 %) of 60 patients
who achieved complete remission on rituximab had a
GI below −27 %, compared with 10 (29.4 %) of 34 patients
who responded (p = 0.0005, LR = 8.82, CI 2.05–37.95),
whereas none of the responders had a GI below −43 %,
compared with 18 % of non-responders (p = 0.0017). The
optimal threshold GI for identifying patients achieving
complete remission on rituximab was calculated at 47.6 %.
Twenty-five (41.6 %) of the sixty patients who achieved re-
mission on rituximab had a GI above this cutoff, compared
with only five (14.7 %) of thirty-four patients who failed to
achieve remission (p = 0.01, LR 2.83, CI 1.20–6.72).
We then applied these threshold GI values to the group
of patients treated with cyclophosphamide. Among the 48
patients who achieved complete remission on cyclophos-
phamide, 16 (33 %) had a GI below −9.25 % compared
with only 8 (17.8 %) of 45 patients who failed to achieve
complete remission, although this difference was not sig-
nificant (p = 0.10). Conversely, 18 (40.0 %) of 45 patients
Table 2 Baseline characteristics of subjects treated with either rituximab or cyclophosphamide and stratified by primary
endpoint outcome
Rituximab p Value Cyclophosphamide p Value
Success, n = 60 Failure, n = 34 Success, n = 48 Failure, n = 45
Age 53.25 56 0.44 51.3 51.9 0.85
Sex 0.52 0.68
Male 45 % 53 % 50 % 56 %
Female 55 % 47 % 50 % 44 %
ANCA-associated vasculitis type 0.66 0.27
PR3 67 % 62 % 60 % 66 %
MPO 33 % 38 % 40 % 34 %
Newly diagnosed at enrollment 48 % 50 % 1.0 56 % 36 % 0.06
BVAS/WG 7.97 ± 0.36 8.09 ± 0.52 0.85 8.42 ± 0.53 7.60 ± 0.47 0.25
ANCA anti-neutrophil cytoplasmic antibodies, BVAS-WG Birmingham Vasculitis Activity Score for Wegener’s granulomatosis, MPO myeloperoxidase, PR3 proteinase 3
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who failed to achieve complete remission had a GI above
47.6 % compared with only 9 (18.8 %) of 48 patients who
achieved complete remission (p = 0.0387, LR 2.13, CI
1.07–4.25).
Using these cutoff values, we define three subsets of
patients, as shown in Fig. 4a: patients with a GI at or
below −9.25 %, patients with a GI between −9.25 % and
47.6 %, and patients with a GI at or above 47.6 %. Of the
187 patients, 44 (24 %) had a GI below −9.25 %. Within
this group, cyclophosphamide was superior to rituximab
in inducing complete remission (67 % vs. 30 %, respect-
ively; p = 0.033). Another 86 patients (46 %) had a GI
between −9.25 % and 47.6 %. Within this group, the
remission rate for patients treated with rituximab was
66 % compared with 55 % for those who received cyclo-
phosphamide (p = 0.38), and it was also similar to the
remission rate among patients randomly assigned to re-
ceive rituximab or cyclophosphamide (Fig. 4b). Finally,
the remaining 57 patients (30 %) had a GI above 47.6 %,
and, within this group, rituximab was significantly more
A
B C
Fig. 3 Granulocyte subpopulations and treatment outcomes. a Representative bidimensional dot plot illustrating the granulocyte subpopulations
identified in an automated manner. Left: Hypergranular granulocytes (definitions in Table 1). Right: Hypogranular granulocytes. FSC forward scatter,
SSC side scatter. b and c Granularity Index at day 0 among patients receiving rituximab and cyclophosphamide, respectively, stratified by treatment
outcome. Data distribution is shown as a notched boxplot (showing minimum, maximum, 25th percentile, median and 75th percentile). An unpaired
Kruskal-Wallis rank-sum non-parametric test was used to calculate significance. WBC white blood cells
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effective than cyclophosphamide in inducing complete
remission (83 % vs. 33 %, respectively; p = 0.0002).
Discussion
We used publicly available flow cytometry data from the
RAVE clinical trial to discover leukocyte markers that
could distinguish patients benefiting from either studied
treatment. Our reanalysis study is important for three
reasons. First, we are highlighting the power of free,
publicly accessible, high-quality raw clinical trial data
available through NIAID ImmPort and the Immune
Tolerance Network. Second, we evaluated and validated
the use of automated gating for the analysis of bulk clin-
ical trial flow cytometry data. Finally, we show that the
reanalysis of existing data can generate new discoveries.
A vast amount of valuable clinical research data is gen-
erated as part of clinical trials; unfortunately, most of
these data are never published [15]. Several measures
are being taken in the hope of encouraging data sharing,
such as the BMJ open data campaign and the AllTrials
initiative [16–18]. We show that raw data released in a
deidentified manner can confirm results achieved by the
Fig. 4 Complete remission rates for patients in the Rituximab in ANCA-Associated Vasculitis (RAVE) trial. a Primary endpoint outcomes among
RAVE trial subjects stratified by the Granularity Index (GI). b Primary endpoint outcomes among RAVE trial subjects treated with either rituximab
or cyclophosphamide in the absence of stratification. Fisher’s exact test was used to calculate significance between rates of complete remission
on rituximab and cyclophosphamide. *10 of the 197 original trial subjects did not have flow cytometry data at baseline
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original investigators, indicating the fidelity of the data-
sharing mechanism from investigator to public user. We
believe this helps address concerns regarding data-
sharing mechanisms raised with the recent calls for the
release of raw individual-level clinical trial data [19, 20].
Given how much raw, publicly available flow cytometry
measurement data were available for our study, we applied
and validated an automated gating technique instead of
manual gating, and reproduced previously published data.
Although ImmPort-FLOCK has been used to analyze flow
cytometry data for several years [6, 11, 12], to the best of
our knowledge, auto-gating has not been evaluated in the
analysis of large-volume flow cytometry data from clinical
trials as a means of reducing the variability associated with
human analysts. Our methodology of using ImmPort-
FLOCK for mass analysis was very accurate in identifying
the lymphocyte and granulocyte populations; however, it
was less accurate in correctly identifying the rarer mono-
cyte population. Accurate assessment of this population
would require additional surface protein staining.
The reanalysis of publicly available molecular data-
bases has previously been shown to lead to clinically
relevant findings, including new oncogenes in cancer
[21], new therapeutic targets for chronic diseases [22]
and new uses for existing drugs [23]. Here, through the
reanalysis of flow cytometry measurement data, we
found that the differential composition of the leukocyte
compartment at baseline was significantly associated
with patients achieving a primary study endpoint in the
RAVE trial.
We used SSC signals to show that patients with AAV
who responded to rituximab had more hypergranular
granulocytes, and fewer hypogranular granulocytes, at
baseline than those who did not respond. Unexpectedly,
this pattern was the opposite in patients receiving cyclo-
phosphamide. It is tempting to speculate that distinct
patient subgroups exist on the basis of granulocyte sub-
sets alone and that they will have differential responses
to rituximab and cyclophosphamide. Although these
findings are novel, the role of neutrophils and ANCA in
disease pathophysiology is well known. ANCA targeting
primary granule antigens expressed on the neutrophils
are known to elicit neutrophil activation and degranula-
tion and subsequently mediate tissue damage [24–26].
After identifying an optimal cutoff value for our GI, we
showed that individuals above or below this threshold
were significantly more likely to either achieve or fail to
achieve remission.
On the basis of these findings, we propose a novel
method of profiling patients on the basis of the GI (Fig. 5).
Under this schema, patients with AAV with a GI at or
below −9.25 % or at or above 47.6 % (about 54 % of patients
with AAV) would significantly benefit from “personalized”
or profiled therapy with cyclophosphamide or rituximab,
respectively. Patients with a GI between −9.25 % and
47.6 % (about 46 % of AAV patients) would be treated with
either therapy according to best clinical judgment, similar
to current treatment practice. We predict that if the RAVE
trial were executed with this profiled design, the overall
remission rate would jump from 58 % (108 of 187) to
69 % (129 of 187) (p = 0.0317).
Our study was limited by the availability of flow cy-
tometry data from the RAVE trial. For example, the sole
antibody panel released by the RAVE investigators did
not specifically evaluate the granulocyte compartment,
such that we were unable to further characterize these
granulocytes. With the anticipated release of additional
antibody panels and other mechanistic data from the
RAVE trial, we believe we will be able to further cha-
racterize these patients’ granulocyte compartment and
test our predictors. Our analysis was also limited by the
small sample size, which precluded us from validating
our model in a separate test sample. Hence, we acknow-
ledge that the model may overfit the data and would re-
quire further validation in future studies.
Although we were unable to validate our findings in
an independent cohort, a study by Grayson et al. pub-
lished while this article was in peer review demonstrated
the presence of a low-density granulocyte (LDG) gene
expression signature in the population of RAVE trial pa-
tients who did not respond to treatment [27]. Whether
this population of LDG corresponds to the hypogranular
granulocyte population described in our present report
is uncertain. However, we believe our results comple-
ment those of Grayson et al. and further demonstrate
that certain patients might benefit from a more targeted
therapy with either cyclophosphamide or rituximab on
the basis of their GI.
Given our findings and the independent findings of
Grayson et al., we believe it would be useful to further
evaluate the granulocyte subset using targeted staining
panels in future clinical studies. Indeed, flow cytometric
analysis of peripheral blood tends to focus on the analysis
of the lymphocyte compartment (and less so the mono-
nuclear compartment) and generally ignores the granulo-
cyte compartment. Routinely assessing this granulocyte
compartment in future clinical studies may help elu-
cidate their role not only in AAV but in other dis-
eases as well.
Conclusions
We identified, within the RAVE trial cohort, novel
changes in granulocyte subpopulations that discriminate
patients with AAV who achieved complete remission on
either rituximab or cyclophosphamide from those who did
not. Equally important, our study demonstrates the utility
of data sharing and encourages further efforts to promote
the dissemination of raw, individual-level clinical trial
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data. We hope our specific findings prompt follow-up
studies that ultimately translate into improved quality of
patient care.
Additional files
Additional file 1: ImmPort-FLOCK Output. Sample FLOCK analysis of
an FCS file (903935_SN05_I019.fcs). Distinct populations identified by
clustering are color-coded. a Dot plot representations of populations
defined by FSC, SSC, CD1c, CD21, CD5, CD19 and CD23. b Summary of
each population described by an expression profile of approximate
marker intensity (1 = negative, 2 = low, 3 = positive, 4 = high). c Gridding
definitions used to identify total lymphocyte, monocyte and granulocyte
populations on the basis of FSC and SSC. (PDF 643 kb)
Additional file 2: Correlation between CD19+ B cells identified
manually versus via ImmPort-FLOCK. RAVE flow cytometry files were
analyzed using ImmPort-FLOCK, and the population of CD19+ lymphocytes
was identified for each of the 1150 files. Publicly available manual gating
results from primary RAVE trial investigators (x-axis) were compared with
ImmPort-FLOCK results (y-axis). A regression coefficient was calculated using
a linear regression model. (PDF 49 kb)
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